The Expression of TP63 As a Biomarker of Early Recurrence in Resected Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 May 25

PMID 38791062

Authors

Chih-Hung Lin

Po-Liang Cheng

Cheng-Yeh Chuang

Yu-Ting Kang

Li-Wen Lee

Tzu-Hung Hsiao

Chung-Ping Hsu

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer ranks among the ten most common cancers worldwide. Despite the adoption of neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by surgery as the standard treatment approach in recent years, the local recurrence rate remains high. In this study, we employed RNA-seq to investigate distinctive gene expression profiles in esophageal squamous cell carcinoma (ESCC) with or without recurrence following a standard treatment course. Our findings indicate that recurrent ESCC exhibits heightened keratinizing and epidermis development activity compared to non-recurrent ESCC. We identified TP63 as a potential candidate for distinguishing clinical outcomes. Furthermore, immunohistochemistry confirmed the trend of TP63 overexpression in ESCC recurrence. Patients with elevated TP63 expression had poorer overall survival and lower 3-year recurrence-free survival. This study underscores the potential of TP63 as a biomarker for detecting cancer recurrence and suggests its role in guiding future treatment options.

References

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

Jiang Y, Jiang Y, Li C, Zhang Y, Dakle P, Kaur H . TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines. Gastroenterology. 2020; 159(4):1311-1327.e19. DOI: 10.1053/j.gastro.2020.06.050. View

Kunisaki C, Makino H, Takagawa R, Yamamoto N, Nagano Y, Fujii S . Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2007; 12(5):802-10. DOI: 10.1007/s11605-007-0385-7. View

Li C, Huang P, Chu P, Chen P, Lin M, Kuo S . Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols. Biomed Res Int. 2016; 2016:6423297. PMC: 5061941. DOI: 10.1155/2016/6423297. View

Yoh K, Prywes R . Pathway Regulation of p63, a Director of Epithelial Cell Fate. Front Endocrinol (Lausanne). 2015; 6:51. PMC: 4412127. DOI: 10.3389/fendo.2015.00051. View

Eckert R, Efimova T, Dashti S, Balasubramanian S, Deucher A, Crish J . Keratinocyte survival, differentiation, and death: many roads lead to mitogen-activated protein kinase. J Investig Dermatol Symp Proc. 2003; 7(1):36-40. DOI: 10.1046/j.1523-1747.2002.19634.x. View

Ye S, Lee K, Park M, Lee J, Kim S . p63 regulates growth of esophageal squamous carcinoma cells via the Akt signaling pathway. Int J Oncol. 2014; 44(6):2153-9. DOI: 10.3892/ijo.2014.2374. View

Moses M, George A, Sakakibara N, Mahmood K, Ponnamperuma R, King K . Molecular Mechanisms of p63-Mediated Squamous Cancer Pathogenesis. Int J Mol Sci. 2019; 20(14). PMC: 6678256. DOI: 10.3390/ijms20143590. View

Devesa S, Blot W, Fraumeni Jr J . Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83(10):2049-53. View

10.

Chen Y, Peng Y, Fan S, Li Y, Xiao Z, Li C . A double dealing tale of p63: an oncogene or a tumor suppressor. Cell Mol Life Sci. 2017; 75(6):965-973. PMC: 11105324. DOI: 10.1007/s00018-017-2666-y. View

11.

Merkow R, Bilimoria K, McCarter M, Chow W, Ko C, Bentrem D . Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2011; 19(2):357-64. DOI: 10.1245/s10434-011-1945-3. View

12.

Barbetta A, Sihag S, Nobel T, Hsu M, Tan K, Bains M . Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery. J Thorac Cardiovasc Surg. 2019; 157(3):1249-1259.e5. PMC: 6534488. DOI: 10.1016/j.jtcvs.2018.09.136. View

13.

Lin C, Li H, Liu Y, Kuo P, Wang W, Lin F . High-CLDN4 ESCC cells harbor stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma. Ther Adv Med Oncol. 2019; 11:1758835919875324. PMC: 6767752. DOI: 10.1177/1758835919875324. View

14.

Han W, Hu C, Fan Z, Shen G . Transcript levels of keratin 1/5/6/14/15/16/17 as potential prognostic indicators in melanoma patients. Sci Rep. 2021; 11(1):1023. PMC: 7806772. DOI: 10.1038/s41598-020-80336-8. View

15.

Lu Z, Zheng S, Liu C, Wang X, Zhang G, Wang F . S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. Clin Transl Med. 2021; 11(7):e459. PMC: 8265170. DOI: 10.1002/ctm2.459. View

16.

Vanbokhoven H, Melino G, Candi E, Declercq W . p63, a story of mice and men. J Invest Dermatol. 2011; 131(6):1196-207. DOI: 10.1038/jid.2011.84. View

17.

Chen C, Li C, Chien C . Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients. World J Surg Oncol. 2018; 16(1):141. PMC: 6046100. DOI: 10.1186/s12957-018-1444-0. View

18.

Lee E, Lee B, Han J, Cho E, Shim Y, Park J . CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int J Cancer. 2008; 123(9):2073-9. DOI: 10.1002/ijc.23598. View

19.

Terzuoli E, Bellan C, Aversa S, Ciccone V, Morbidelli L, Giachetti A . ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output. Cancers (Basel). 2019; 11(12). PMC: 6966589. DOI: 10.3390/cancers11121963. View

20.

Li Y, Giovannini S, Wang T, Fang J, Li P, Shao C . p63: a crucial player in epithelial stemness regulation. Oncogene. 2023; 42(46):3371-3384. PMC: 10638092. DOI: 10.1038/s41388-023-02859-4. View